
FIREFLY NEUROSCIENCE, INC.
80
Recent developments highlight Firefly Neuroscience's technological integrations, AI biomarker discoveries, and strategic collaborations advancing its neuroscience platform applications.
- Firefly Neuroscience announced integration of its Evoke EEG platform with RadialOS, enhancing its technology ecosystem [N1].
- The company unveiled AI-driven biomarker discovery technology for PTSD, expanding its diagnostic capabilities [N2].
- Firefly discovered new brain-wave biomarkers for ADHD, indicating progress in neurodevelopmental disorder diagnostics [N3].
- It inked a deal for use of its FDA-cleared BNA platform in neuroscience research, supporting commercial partnerships [N4].
- Firefly collaborates with Heidelberg University Hospital on EEG studies to advance precision neuroscience research [N5].
Firefly Neuroscience, Inc. operates in the neuroscience technology sector, focusing on brain health diagnostics and research tools. Its core product is the FDA-cleared Brain Network Activation (BNA) platform, which utilizes EEG and related technologies to assess brain function. The company collaborates with medical and academic institutions to advance precision neuroscience and develop biomarkers for neurological and psychiatric conditions. Firefly's technology applications include early diagnosis of Alzheimer's disease, ADHD, and PTSD. The company has engaged in partnerships to expand the use of its platforms and integrates AI to enhance biomarker discovery. Firefly is publicly listed and included in the Russell Microcap® Index.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Firefly Neuroscience, Inc. is a neuroscience technology company focused on brain health diagnostics and research. The company develops and commercializes the FDA-cleared Brain Network Activation (BNA) platform and related EEG-based technologies. Recent developments include collaborations with academic institutions, integration of EEG platforms with software ecosystems, and AI-driven biomarker discovery for neurological conditions such as PTSD and ADHD. The latest SEC 10-Q filing as of September 30, 2026, reports quarterly revenue of $647,000, a net loss of $1.48 million, and strong liquidity with a current ratio of 4.48 and cash equivalents of $8.02 million. Risk factors remain consistent with prior disclosures.
Firefly Neuroscience's advancements in AI-driven biomarker discovery and integration of EEG platforms with software ecosystems demonstrate technological innovation. Its collaborations with reputable institutions and expansion into multiple neurological conditions suggest a broadening application base. Strong liquidity reported in recent SEC filings supports ongoing research and development activities. The company's inclusion in market indices reflects growing market recognition.
The company reported a net loss in the latest quarter, indicating ongoing operational expenses exceeding revenues. Revenue remains modest relative to expenses, reflecting early-stage commercialization. The neuroscience diagnostics market is competitive and subject to regulatory and reimbursement challenges. Dependence on continued research collaborations and successful technology adoption poses execution risks. No material changes in risk factors were disclosed, but inherent risks in biotech and medical device sectors remain.
Firefly Neuroscience's moat is anchored in its FDA-cleared BNA platform, which provides a proprietary technology for brain function assessment using EEG data. The company's collaborations with academic and medical institutions support ongoing research and validation, enhancing its scientific credibility. Its integration of AI-driven biomarker discovery and multi-modal diagnostic approaches (combining EEG with MRI) further differentiate its offerings. The regulatory clearance and specialized technology create barriers to entry for competitors in the brain health diagnostics space.
• Financial Risk: The company reported a net loss of $1.48 million for the quarter ended September 30, 2026, with modest revenue of $647,000, indicating ongoing need for capital to fund operations [S2].
• Market and Commercialization Risk: Firefly Neuroscience operates in a competitive neuroscience diagnostics market with challenges in technology adoption, reimbursement, and regulatory compliance.
• Execution Risk: Successful integration of AI-driven biomarker discovery and platform partnerships depends on effective execution and continued research collaborations.
• Regulatory Risk: The company's products require regulatory clearance and ongoing compliance, which can impact commercialization and market access.
Business trends: Expansion of AI-driven biomarker discovery and integration of EEG platforms with software ecosystems; broadening applications in neurological diagnostics.
Execution milestones: Advancement of commercial partnerships, ongoing research collaborations with academic institutions, and maintenance of strong liquidity.
Key risks: Financial sustainability amid net losses, market adoption challenges, execution of technology integration, and regulatory compliance risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Firefly Neuroscience develops neuroscience technologies focused on brain health, including FDA-cleared Brain Network Activation (BNA) platform.
- The company engages in collaborations with academic and medical institutions, such as Heidelberg University Hospital, to advance precision neuroscience research using EEG studies [N5].
- Firefly Neuroscience has integrated its Evoke EEG platform with RadialOS, indicating efforts to enhance its technology ecosystem [N1].
- The company unveiled AI-driven biomarker discovery technology for PTSD, demonstrating application of AI in neuroscience diagnostics [N2].
- Firefly discovered new brain-wave biomarkers for ADHD, highlighting its focus on neurodevelopmental disorders [N3].
- It has inked deals for use of its FDA-cleared BNA platform in neuroscience research, showing commercial partnerships [N4].
- Firefly Neuroscience joined the Russell Microcap® Index following its Nasdaq listing, indicating its market presence [N6].
- The company reported advancements in Alzheimer's diagnosis through combined EEG/ERP and volumetric MRI technologies, reflecting multi-modal diagnostic approaches [N7].
- Firefly Neuroscience raised $8.8 million from warrant exercises to support brain health innovation initiatives [N5].
- The latest SEC 10-Q filing as of 2026-09-30 reports cash and equivalents of $8.02 million, current assets of $9.04 million, current liabilities of $2.02 million, yielding a current ratio of 4.48 and cash ratio of 3.97, indicating strong liquidity [S2].
- Revenue for the quarter ended 2026-09-30 was $647,000 with a net loss of $1.48 million and basic EPS of -$0.07 [S2].
- Risk factors disclosed in the latest 10-Q filing indicate no material changes from prior annual and quarterly reports [S2][S1].
Generated 2026-11-10
- S1 | 2026-03-31 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-09-17 | www.nasdaq.com | Firefly Neuroscience To Integrate Evoke EEG Platform With RadialOS | https://www.nasdaq.com/articles/firefly-neuroscience-integrate-evoke-eeg-platform-radialos
- N2 | 2026-06-02 | www.nasdaq.com | Firefly Neuroscience Unveils AI-Driven Biomarker Discovery For PTSD | https://www.nasdaq.com/articles/firefly-neuroscience-unveils-ai-driven-biomarker-discovery-ptsd
- N3 | 2026-03-13 | www.nasdaq.com | FireFly Surges After Discovering New Brain-Wave Biomarkers For ADHD | https://www.nasdaq.com/articles/firefly-surges-after-discovering-new-brain-wave-biomarkers-adhd
- N4 | 2025-07-14 | www.nasdaq.com | Firefly Neuroscience Inks Deal For Use Of Its FDA-Cleared BNA Platform In Neuroscience Research | https://www.nasdaq.com/articles/firefly-neuroscience-inks-deal-use-its-fda-cleared-bna-platform-neuroscience-research
- N5 | 2025-07-14 | www.nasdaq.com | Firefly Neuroscience, Inc. Collaborates with Heidelberg University Hospital on EEG Study of 15q13.3 CNVs to Advance Precision Neuroscience | https://www.nasdaq.com/articles/firefly-neuroscience-inc-collaborates-heidelberg-university-hospital-eeg-study-15q133-cnvs
- N6 | 2025-06-23 | www.nasdaq.com | Firefly Neuroscience, Inc. to Join Russell Microcap® Index Following Nasdaq Listing | https://www.nasdaq.com/articles/firefly-neuroscience-inc-join-russell-microcapr-index-following-nasdaq-listing
- N7 | 2025-06-20 | www.nasdaq.com | Firefly Neuroscience Reports Advancements in Alzheimer's Diagnosis through Combined EEG/ERP and vMRI Technologies | https://www.nasdaq.com/articles/firefly-neuroscience-reports-advancements-alzheimers-diagnosis-through-combined-eeg-erp
- N8 | 2025-05-06 | www.nasdaq.com | Firefly Neuroscience Issues Correction on Acquisition Announcement of Evoke Neuroscience, Inc. | https://www.nasdaq.com/articles/firefly-neuroscience-issues-correction-acquisition-announcement-evoke-neuroscience-inc
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


